Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2008 Jul;7(7):1900–1908. doi: 10.1158/1535-7163.MCT-08-0012

Figure 2. NDGA inhibits survival of BT474 parental and trastuzumab-refractory breast cancer cells.

Figure 2

Figure 2

(A) Parental BT474 HER2-overexpressing breast cancer cells (BT-parental), BT474-derived trastuzumab-refractory pool 2 (BT-HRp2) and pool 3 (BT-HRp3) cells were treated with 0 or 20 μg/mL trastuzumab (Tras) for 6 d, and then counted by trypan blue exclusion. Cell viability is expressed as a percentage of untreated cells per line; percentages are shown above each bar with standard deviation between replicates. The results confirm trastuzumab resistance of BT474 pool 2 and pool 3 cells relative to parental cells. (B) BT-parental, BT-HRp2, and BT-HRp3 were treated with 0, 25, 50, or 100 μM NDGA for 72 h, at which point trypan blue exclusion analysis was performed. Experiments were done in triplicate, and repeated at least twice. Cell viability is expressed as a percentage of untreated cells per line, with error bars representing standard deviation between replicates. NDGA suppressed growth and survival of the parental and trastuzumab-refractory HER2-overexpressing BT474 breast cancer cells, with resistant cells showing increased sensitivity to NDGA versus parental cells.